Combination of pimavanserin and cytochrome p450 modulators
AssigneeACADIA Pharmaceuticals Inc.
InventorAndrew Parkinson
Life of this patent
Estimating the term…
Abstract
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
Claims32
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of a compound of Formula (I) or a pharmaceutical acceptable salt thereof:
- wherein the dose is at least 20% lower than a dose of the compound of Formula (I) or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
A method for treating a disease or disorder in a patient who is currently taking a first dose of a compound of Formula (I) or a pharmaceutical acceptable salt thereof:
- comprising:
- administering to the patient a cytochrome P450 inhibitor;
- and
- reducing the first dose to a second dose of the compound of Formula (I) or a pharmaceutical acceptable salt,
- wherein the second dose is at least 20% lower han the first dose.
31-32. (canceled)
A method of treating hallucinations or delusions associated with Parkinson's disease psychosis in a patient who is taking a CYP3A4 inhibitor, the method comprising administering 10-24 mg daily of pimavanserin tartrate to the patient.
Dependencies are inferred from the claim text.